Delays in Progress at a U.S. Emerging Medical Device Manufacturer and an Investment Valuation Loss
First written in FY2018-Q3. 1 of 2 entries say "Materialised", first in FY2018-Q3. Latest entry: FY2018.
Yamashita Health Care Holdings moved to the "Worse" side of this theme in 2018, 4 years before the typical company in this theme (2022).
1 other company's latest entry also says "Restated".
- FY2018RestatedAnnual report
「Although an impairment loss on investment securities of ¥67 million and an impairment loss on fixed assets of ¥26 million were recognized under extraordinary gains and losses, net income attributable to owners of the parent was ¥220 million.」
The ¥67 million impairment loss on investment securities was reaffirmed as part of the full-year results. - FY2018-Q3MaterialisedAnnual report
「The business progress of the U.S. medical device start-up in which the Company had invested fell significantly behind the initial plan, and the substantial value of the investment declined markedly. Accordingly, the Company recognized an impairment loss on investment securities of ¥67 million as an extraordinary loss.」
The delay in business progress and decline in the value of the investment actually occurred and were recognized as a ¥67 million impairment loss.